Related Experiment Video
Updated: May 29, 2025
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
3.6K
Localization Matters: Impacts of PEG-J Localization in Intestinal Levodopa Therapy for Parkinson's Disease
Philipp Klocke1, Moritz A Loeffler1, Idil Cebi1
1Centre for Neurology, Department for Neurodegenerative Diseases, and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Movement Disorders Clinical Practice
|February 4, 2025
Summary
Intestinal levodopa gel absorption is similar in the duodenum and jejunum. However, jejunal placement of the device is crucial for stabilizing motor fluctuations in Parkinson's disease patients.
Area of Science:
- Neurology
- Gastroenterology
- Pharmacology
Background:
- Limited real-world data exists on levodopa absorption in the duodenum versus jejunum.
- Understanding intestinal levodopa resorption is key for Parkinson's disease management.
Purpose of the Study:
- To investigate how intestinal levodopa gel application site impacts levodopa dosing.
- To evaluate the effect of intestinal levodopa gel application site on clinical outcomes in Parkinson's disease.
Main Methods:
- A multicenter retrospective analysis of 111 Parkinson's disease patients.
- Compared levodopa equivalent dosage changes after switching to intestinal continuous infusion therapy.
- Stratified analysis based on percutaneous gastrojejunostomy (PEG-J) tube localization (duodenal vs. jejunal) for levodopa-carbidopa (LCIG) and levodopa-carbidopa-entacapone (LECIG) intestinal gels.
Main Results:
- Levodopa equivalent dosage changes were similar between duodenal and jejunal PEG-J tube positions.
- Persistent motor fluctuations were more common in patients with duodenal PEG-J placements (44.4%) compared to jejunal (21.9%).
- Dislocation of PEG-J tubes from jejunum to duodenum led to the re-emergence of motor fluctuations.
Conclusions:
- Levodopa-carbidopa intestinal gel (LCIG) and levodopa-carbidopa-entacapone intestinal gel (LECIG) show comparable absorption in both duodenal and jejunal segments.
- Jejunal positioning of PEG-J tubes is critical for effectively stabilizing motor fluctuations in Parkinson's disease patients.
Related Concept Videos
01:24Parkinson's Disease: Treatment
192
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
192
01:15Parkinson's Disease: Overview
447
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
447
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
243
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
243
01:21Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH
998
Drug absorption within the gastrointestinal (GI) tract is a complex process influenced by several critical factors, including the site pH, the drug's dissociation constant (pKa), and the drug's lipophilicity. The GI tract exhibits a pH gradient, with an acidic environment in the stomach and a more alkaline environment in the small intestine. This pH variation directly affects the ionization state of drugs.
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
998
01:25Factors Influencing Drug Absorption: Disease States and Pharmacology
415
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
415
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
204
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
204